Evidence map›Paper›PMID 40799992›Full record

ArticleMaterials today. Bio2025

Top-down engineered micron-cell derived nanovesicles encapsulating curcumin targeting the 3R strategy (remove, remodel, repair) for Alzheimer's disease therapy.

Jianjian Chu, Hui Hu, Wei Xu, Xinyu Lu, Honglei Zhou, Mengqi Hao, Li Wang, Siqi Li, Wenbo Ji, Gang Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jianjian ChuDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Hui HuDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wei XuDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Xinyu LuDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Honglei ZhouDepartment of General Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Mengqi HaoDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Li WangDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Siqi LiDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Wenbo JiDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, China.
Gang LiDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yi LuoNew Drug Discovery and Development, Biotheus Inc, Zhuhai, China.
Jie GaoChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Dongya HuangDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yan LiuDepartment of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
You YinDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD), a global health crisis exacerbated by aging populations, demands innovative therapeutic strategies. Curcumin, a natural compound with anti-aging and anti-inflammatory properties, holds promise for AD treatment but is hindered by poor bioavailability. Here, we developed curcumin-loaded nanovesicles (NV-CUR) derived from brain-homing B16 melanoma cells to overcome these limitations. NV-CUR enhanced the solubility, stability, and blood‒brain barrier (BBB) penetration of curcumin, enabling systemic delivery in aged 3 × Tg AD mice. Our 3R strategy for removing senescent cells, remodeling the neuroinflammatory microenvironment, and repairing neuronal damage was comprehensively validated. NV-CUR effectively cleared p16

Indexed as

AgingAlzheimer's diseaseblood‒brain barrierCurcuminNanovesicles

Identifiers

PMID40799992
PMCPMC12341626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.